The University of Oregon and mAbDx have finalized a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products. CTIP2 (also known as BCL11b) is a zinc finger transcription factor essential for transcriptional control of hundreds of genes encoding key proteins in cell signaling pathways during normal proliferation and development of the epidermis, immune system and CNS. Notably, CTIP2 protein expression levels are altered in Head and Neck Squamous Cell Carcinoma (HNSCC, the 6th most common cancer in the US) and in thymic (T-cell) lymphomas.